Bluebird Bio, an organization that steered three gene therapies to FDA approval however struggled to commercialize them, has discovered the money it must...
Neuroscience drug developer Lundbeck is increasing its scope to epilepsy by way of the $2.6 billion acquisition of Longboard Prescribed drugs, an organization...